Philips introduces SmartIQ to address the trade-off between image quality and radiation dose in coronary procedures
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Philips (NYSE:PHG) introduced SmartIQ, a coronary imaging technology for Azurion systems, designed to improve image quality while optimizing radiation and contrast dose. An ultra-low dose protocol for coronary procedures employs over 50% less X-ray radiation than the lowest ClarityIQ settings.
SmartIQ is CE-marked and available on new and existing Azurion systems in Europe and selected markets, with initial pilot data suggesting higher image quality at maintained or reduced radiation and contrast dose. The ongoing RADIQAL trial has reached 60% enrollment; SmartIQ is not yet cleared in the United States.
Positive
- Ultra-low dose coronary protocol uses over 50% less X-ray radiation than lowest ClarityIQ settings
- Blinded pilot study suggests SmartIQ images were preferred and scored higher on image quality
- SmartIQ builds on ClarityIQ platform, previously associated with 23%–83% radiation exposure reductions
- RADIQAL trial has reached 60% of total enrollment and completed European site enrollment
- SmartIQ is CE-marked and available on new and existing Azurion systems in Europe and selected markets
Negative
- SmartIQ technology is not yet cleared for use in the United States
- Radiation dose reduction potential of SmartIQ remains under investigation in the ongoing RADIQAL trial
Details
News Market Reaction – PHG
On May 18, the day this news came out, PHG closed 3.25% above the previous close.
Data tracked by StockTitan Argus for the May 18 session.
Key Figures
- Radiation dose reduction
- over 50% less X-ray radiation dose
- Ultra-low dose protocol for coronary procedures vs lowest ClarityIQ settings
- Radiation reduction range
- 23% to 83% reduction
- ClarityIQ-associated exposure reductions across clinical areas
- Dose reduction Azurion M12
- 58% reference air kerma reduction
- SmartIQ ultra-low left coronary 15 fps cine runs vs low ClarityIQ
- Dose reduction Azurion M20
- 62% reference air kerma reduction
- SmartIQ ultra-low left coronary 15 fps cine runs vs low ClarityIQ
- Frame rate
- 15 fps
- SmartIQ ultra-low left coronary cine run protocol
- Trial enrollment progress
- 60% of total enrollment
- RADIQAL trial assessing SmartIQ vs ClarityIQ
- Fluoroscopy limit
- <88 mGy/min
- Reference air kerma rate limit in FDA 21CFR1020.32 and IEC 60601-2-54
Historical Context
-
All AGM 2026 proposals approved, including key board and CEO reappointments.
-
Reported strong order intake, comparable sales growth, and margin expansion in Q1.
-
Launched Bridge Plus Occlusion Balloon for managing rare SVC tears in lead extraction.
-
Received FDA 510(k) clearance for Rembra CT/RT platform, expanding CT access and throughput.
-
Gained FDA 510(k) clearance for Spectral CT Verida, an AI-powered spectral CT system.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
ce-marked regulatory
reference air kerma medical
fluoroscopy medical
randomized clinical trial medical
mGy/min medical
21cfr1020.32 regulatory
iec 60601-2-54 regulatory
cine runs medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
May 18, 2026
- Greater differentiation of clinical details through contrast-rich images with reduced background noise
- For coronary procedures, a new ultra-low dose protocol employs over
50% less X-ray radiation dose [1] - First SmartIQ clinical pilot study published in JSCAI, further building on Philips’ strong track record in evidence generation [2]
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced Philips SmartIQ, a breakthrough coronary imaging technology for its Azurion image-guided therapy. Developed in collaboration with leading cardiovascular centers, SmartIQ is designed to address one of the field’s most fundamental challenges: the trade-off between image quality and radiation exposure for patients and clinical staff. It aims to empower clinicians with exceptional image quality, enabling them to see exactly what they need, while it aims to provide reassurance that X-ray dose and contrast levels are optimized.
“With this new imaging technology, we can go really low in dose and achieve even better image quality. It’s a win-win,” said Dr. Mark Winkens, Interventional Cardiologist at Elisabeth-TweeSteden Hospital (ETZ) in Tilburg, the Netherlands.
Philips will showcase SmartIQ at EuroPCR 2026 (May 19–22, Paris, France), where attendees can experience the technology firsthand and hear directly from early clinical adopters. During dedicated clinical sessions, clinicians will share initial case experiences and present real-world multicenter results. Leveraging Philips’ strong track record in evidence generation, the first blinded clinical pilot study evaluating SmartIQ was recently published in Journal of the Society for Cardiovascular Angiography & Interventions. The study suggests that the algorithm scored higher on image quality and was preferred in the vast majority of blinded comparisons, while maintaining or lowering radiation and contrast dose.
The technology builds on Philips’ industry-leading ClarityIQ platform, which has previously been associated with radiation exposure reductions between
SmartIQ represents the next step forward in image quality and dose management for coronary imaging. It includes an ultra-low dose protocol for coronary procedures that employs over
“For too long, clinicians have had to choose between image quality and radiation dose during coronary procedures,” said Mark Stoffels, Business Leader Image-Guided Therapy Systems at Philips. “With our breakthrough SmartIQ technology, we believe that trade-off no longer has to define coronary imaging. This is not an incremental step forward – it represents one of Philips’ boldest advances yet in helping clinicians see what they need while aiming to further reduce exposure for patients and clinical teams.”
“Image quality is the foundation of every decision we make in the cath lab. SmartIQ has genuinely surprised us. It delivers the clarity we need at very low radiation dose levels,” said Dr. Nicolaj Brejnholt Støttrup, Interventional Cardiologist at Aarhus University Hospital in Aarhus, Denmark.
SmartIQ is the latest example of Philips’ long-term commitment to reducing radiation exposure across image-guided therapy. Together with innovations such as DoseAware, LumiGuide and EchoNavigator, it reflects a system-wide approach designed to help clinicians achieve the image quality they need while continuing the aim to reduce radiation exposure for patients and staff.
SmartIQ is CE-marked and available in Europe and selected markets on both new and existing Azurion systems. The technology is not yet cleared for use in the United States.
[1] Compared with the low ClarityIQ setting on Azurion systems, SmartIQ ultra-low left coronary 15 fps cine runs specify average reference air kerma reductions of
[2] Assar et al., Exploring a Novel Processing Algorithm to Improve Image Quality and Reduce X-Ray and Contrast Dose for Coronary Angiography: A Blinded Pilot Study. Journal of the Society for Cardiovascular Angiography & Interventions, 2026, 105343
[3] In 37 individual comparative studies, Philips ClarityIQ was associated with reductions in patient radiation exposure. The results of the application of dose reduction techniques will vary depending on the clinical task, patient size, anatomical location and clinical practice. The interventional radiologist assisted by a physicist as necessary has to determine the appropriate settings for each specific clinical task. See website: https://www.philips.com/clinicallyproven
[4] The radiation dose reduction potential of SmartIQ is currently investigated in the RADIQAL trial. The RADIQAL trial is a multi-center randomized clinical trial to assess the impact of SmartIQ on radiation dose compared to the current ClarityIQ while maintaining procedural performance. This includes a comparison to the limitation of the reference air kerma rate in fluoroscopy of <88 mGy/min as stated in FDA 21CFR1020.32 and international standard IEC 60601-2-54. For details about RADIQAL, visit https://clinicaltrials.gov/study/NCT06944509.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.